Cell Line Development Feature

Cell line development refers to the process of establishing a stable, immortalized population of cells derived from a specific tissue or organism. This involves isolating cells from the desired tissue source and growing them in laboratory conditions that support their continued growth and survival.

The goal of cell line development is to create a cell line that can be used in various research applications, such as drug discovery, biotechnology, and cell-based assays. These cell lines are often genetically modified or selected for specific characteristics, allowing them to be used as models to study disease mechanisms, test potential therapies, or produce desired molecules.

This editorial feature shares expert resources on the methods and technologies used in the development of cell lines and how these cells are optimized for applications including the study of disease mechanisms, screening therapeutics, and in the production of biotherapeutics.

The next generation of capability

Droplet microfluidics for single cell analysis

Droplet microfluidics is an established technology for single-cell analysis, characterization, and selection. Cells are encapsulated in droplets of a suitable aqueous media contained in an oil carrier fluid, and the droplets are stabilized with a surfactant. Explore the real-world benefits of droplet microfluidics and see how this technique is revolutionizing single-cell analysis and selection in biopharma in this expert guest editorial.

Read expert article

Robust characterization of heterogeneity in CAR T cell cytotoxicity

The detection and analysis of single cells are critical in advancing CAR T cell therapy and understanding its mechanisms of action, such as cytotoxicity. Traditional bulk assays fall short of revealing cellular heterogeneity, which limits their effectiveness in evaluating therapeutic potency. The Xdrop single-cell assay from Samplix addresses this challenge by providing high-resolution insights into CAR T cell-mediated cytotoxicity.

Download free resource

The workflow for a combined granzyme B (GzmB) and cell killing assay with single-cell resolution in droplets. Before encapsulation in double-emulsion droplets, the target and effector cells are separately stained. Using Xdrop and the Xdrop DE50 Cartridge, CAR T cells or un-transduced T cells (UTDs) are co-encapsulated with target cells (JeKo-1) in DE50 droplets together with complete RPMI, propidium iodide (PI), and FAM-labeled GzmB peptide substrate. The assay and incubation occur within the droplets. Secreted GzmB activity is revealed by green fluorescence emission after GzmB cleaves the substrate. Cell death is indicated by PI. After incubation, DE50 droplets can be analyzed by microscopy and/or flow cytometry.

Best practices for optimizing cell line development processes

The steps to create a stable, manufacturing cell line include host cell line selection, engineering of the expression vector, transfection, cloning and cell expansion, as well as various screening steps to select the clone with the highest cell viability, growth, expression level, stability and product quality. In this eBook, Dr. Jon Dempsey discusses his thoughts regarding best practices for optimizing cell line development (CLD) processes.

Download free resource

Lab equipment essentials for successful cell line development

While high-throughput analytical instruments often take center stage, everyday lab essentials also play a critical role in creating the stable, high-producer cell lines needed for commercial manufacturing. This guide will introduce you to lab essentials designed to help streamline routine cell line development tasks. Learn how to achieve more accurate results, avoid contamination, and simplify workflows with reliable and easy-to-use products.

Download free eBook

Cell line development and synthetic biology workflows driven by automation

Lori Euler and Chris Saenz from Beckman Coulter Life Sciences unveil strategies to elevate efficiency in synthetic biology workflows through automation, offering practical approaches to streamline processes and optimize productivity. In the second half of this SLAS 2024 presentation, Brian Murphy and Peter Braun, also of Beckman Coulter Life Sciences, offer valuable insights into refining the cell line development processes using automated antibody analytics on the Biomek i5 Liquid Handler. Don't miss this opportunity to learn from industry leaders about the transformative impact of automation and advanced analytics on cell line development, tackling bottlenecks, and accelerating drug development timelines.

Watch presentation on demand